## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($39.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference**
- Source: 01net | 20251230T000944 | Somewhat-Bullish | Relevance: 100%
- Veracyte, Inc. announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. A live audio webcast will be available on Veracyteâ€™s website, with a replay accessible for 30 days. Veracyte is a global diagnostics company focused on transforming cancer care with high-performing tests driven by genomic and AI capabilities.

**2. Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference**
- Source: Business Wire | 20251229T210943 | Somewhat-Bullish | Relevance: 100%
- Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company, announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. Pacific Time. A live audio webcast and subsequent replay will be available on Veracyte's investor relations website. The company aims to transform cancer care through its Veracyte Diagnostics Platform, offering high-performing cancer tests driven by genomic data, AI capabilities, and evidence generation.

**3. Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)**
- Source: Insider Monkey | 20251230T160858 | Somewhat-Bullish | Relevance: 100%
- Morgan Stanley has initiated coverage of Veracyte, Inc. (NASDAQ: VCYT) with an Underweight rating and a price target of $48, citing increasing bright spots in the Life Science Tools and Diagnostics markets. Veracyte has also boosted its full-year 2025 guidance for total sales, testing revenue, and adjusted EBITDA margin. Although acknowledging the potential of VCYT, the article suggests that other AI stocks might offer higher returns in a shorter timeframe.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $48 | $40 | +20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 22 ($4.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $4.9M in recent transactions.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (1 raises, avg +20%). Insider selling cluster ($4.9M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.3B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 26.2 |
| Current P/E | 25.6 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.0%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.29x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: -DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.72% (CS: 38) | Neutral |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.290x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $42.10
- **Stop Loss:** $39.10 (7.1% risk)
- **Target:** $45.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 480
- **Position Value:** $20,208.00
- **Portfolio %:** 20.21%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*